Merck & Co., Inc. (NYSE: MRK) is one of the. The company announced that the US FDA approved ENFLONSIA™ (clesrovimab-cfor) for ...

The Centers for Disease Control and Prevention (CDC) has adopted new vaccine recommendations that expand protection for respiratory syncytial virus (RSV) and meningococcal disease, backing products ...

The new RSV recommendation calls for a single dose of vaccine for adults age 50 to 59 years who are at increased risk of ...

The expanded recommendation is good news for Moderna, Pfizer, and GSK, which all sell RSV vaccines for older adults. Moderna ...

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60 ...

The U.S. Centers for Disease Control and Prevention has accepted recommendations made by a panel of vaccine experts in April, ...

There have been almost 50,000 cases of RSV recorded this year, but only a select group can access the free vaccine, with other vulnerable Australians needing to fork out hundreds of dollars.

RSV-associated hospitalizations for children aged 8-19 months or 20-59 months were not significantly different between the two time periods, and slightly higher in the 2024-2025 period.

Common RSV symptoms in many people include "a runny nose, cough, sneezing and fever – basically mild cold-like symptoms that are mostly contained to the upper respiratory tract," says Dr. Alison ...

Parents may be more aware of the dangers of RSV following the surge in infections two years ago, which occurred after COVID-19 lockdowns left some children unexposed to the virus and more ...

RSV is the leading cause of bronchiolitis and pneumonia (both chest infections) in young children. Each year, at least one in 200 children under five are hospitalised with RSV in Australia.